Geode Capital Management LLC Has $703,000 Position in Quince Therapeutics, Inc. (NASDAQ:QNCX)

Geode Capital Management LLC increased its stake in shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) by 10.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 375,932 shares of the company’s stock after purchasing an additional 36,807 shares during the quarter. Geode Capital Management LLC owned approximately 0.85% of Quince Therapeutics worth $703,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Scharf Investments LLC acquired a new position in shares of Quince Therapeutics during the fourth quarter worth $170,000. Virtu Financial LLC acquired a new position in Quince Therapeutics in the 4th quarter worth about $55,000. Finally, Anfield Capital Management LLC bought a new position in Quince Therapeutics in the fourth quarter valued at about $50,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. D. Boral Capital reduced their price target on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Oppenheimer assumed coverage on shares of Quince Therapeutics in a report on Monday, March 24th. They set an “outperform” rating and a $10.00 target price on the stock. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, Quince Therapeutics presently has a consensus rating of “Buy” and an average price target of $8.00.

Quince Therapeutics Price Performance

Shares of QNCX opened at $1.08 on Friday. The business has a 50-day moving average of $1.26 and a 200-day moving average of $1.51. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The company has a market capitalization of $47.65 million, a price-to-earnings ratio of -0.87 and a beta of 0.74. Quince Therapeutics, Inc. has a 1 year low of $0.51 and a 1 year high of $2.45.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings results on Monday, March 24th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. As a group, equities research analysts anticipate that Quince Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.